PCSK9

Assets acting on this target.

Class
PCSK9-targeted therapeutic

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein secreted mainly by the liver that regulates how many low-density lipoprotein receptors (LDLRs) appear on the surface of liver cells. LDLRs are responsible for pulling LDL cholesterol ('bad cholesterol') out of the bloodstream. Normally, after an LDLR captures a cholesterol particle, it recycles back to the cell surface to work again. PCSK9 binds to the LDLR and redirects it toward destruction instead, reducing the number of receptors available and leaving more LDL cholesterol circulating in blood. People with naturally occurring PCSK9 loss-of-function variants have lifelong low LDL cholesterol and reduced rates of atherosclerotic cardiovascular disease, while gain-of-function variants cause a hereditary form of very high cholesterol. This genetic evidence established PCSK9 as a rational drug target: blocking its activity or reducing its production allows more LDLR to persist, increasing clearance of LDL cholesterol from the blood. Because elevated LDL cholesterol is a major driver of atherosclerosis, heart attack, and stroke, PCSK9-targeted therapies are used, often alongside other cholesterol-lowering treatments, to bring LDL cholesterol down further in people at cardiovascular risk.

By indication

Related mechanisms

PCSK9 drugs compared

19 drugs, stage by indication
19 drugs acting on PCSK9: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AlirocumabPraluentRegeneron Pharmaceuticals, Sanofimonoclonal antibodyApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Homozygous Familial Hypercholesterolemia
EvolocumabRepathaAmgenmonoclonal antibodyApprovedApproved in Atherosclerotic Cardiovascular Disease; Approved in Homozygous Familial Hypercholesterolemia
InclisiranLeqvioAlnylam Pharmaceuticals, NovartisRNAi (siRNA)ApprovedApproved in Homozygous Familial Hypercholesterolemia; Phase 3 in Atherosclerotic Cardiovascular Disease
EbronucimabAkeso, Hubei Jumpcan Pharmaceuticalmonoclonal antibodyPhase 3Phase 3 in Atherosclerotic Cardiovascular Disease
EnlicitideLipfendraMerck & Co.peptidePhase 3Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 3 in Hypercholesterolemia
LaroprovstatAstraZenecasmall moleculePhase 3Phase 3 in Atherosclerotic Cardiovascular Disease; Phase 2 in Dyslipidemia
LerodalcibepLerocholEverest Medicines (Beijing) Co., Ltd., LIB Therapeutics, Sun Pharmaceutical Industriessmall protein (recombinant fusion protein)Phase 3Phase 3 in Atherosclerotic Cardiovascular Disease
OngericimabJunshidaShanghai Junshi Biosciencemonoclonal antibodyPhase 3Phase 3 in Atherosclerotic Cardiovascular Disease
QLC7401Qilu Pharmaceutical, Suzhou Ribo Life ScienceRNAi (siRNA)Phase 3Phase 3 in Atherosclerotic Cardiovascular Disease
RecaticimabJiangsu Hengrui Pharmaceuticalsmonoclonal antibodyPhase 3Phase 3 in Atherosclerotic Cardiovascular Disease
SAL003Shenzhen Salubris Pharmaceuticalsmonoclonal antibodyPhase 3Phase 3 in Atherosclerotic Cardiovascular Disease
SYH2053CSPC Pharmaceutical GroupRNAi (siRNA)Phase 3Phase 3 in Atherosclerotic Cardiovascular Disease
TafolecimabSintbiloInnovent Biologicsmonoclonal antibodyPhase 3Phase 3 in Atherosclerotic Cardiovascular Disease
DNV001Hangzhou Dinovate BiotechRNAi (siRNA)Phase 2Phase 2 in Atherosclerotic Cardiovascular Disease
HRS-1301Jiangsu Hengrui Pharmaceuticalssmall moleculePhase 2Phase 2 in Atherosclerotic Cardiovascular Disease; Phase 2 in Hyperlipidemia
COR-1004Corsera HealthNot recordedPhase 1Phase 1 in Atherosclerotic Cardiovascular Disease
HS-10510Hansoh Pharmaceutical Groupsmall moleculePhase 1Phase 1 in Atherosclerotic Cardiovascular Disease
RBD7022Suzhou Ribo Life ScienceRNAi (siRNA)Phase 1Phase 1 in Atherosclerotic Cardiovascular Disease
RN0191Rona TherapeuticsRNAi (siRNA)Phase 1Phase 1 in Atherosclerotic Cardiovascular Disease

← all mechanisms